Tag: Gates Foundation
-
Qure.ai Secures Gates Foundation Grant to Advance Open-Source AI for Lung Ultrasound
Qure.ai Wins Gates Foundation Grant to Accelerate AI Lung Ultrasound In a move that could reshape how lung health is diagnosed in underserved communities, Qure.ai has received a multimillion-dollar grant from the Bill & Melinda Gates Foundation. The funding is earmarked to develop open-source datasets and AI tools designed to detect lung disease using ultrasound…
-
Samburu Wa-Shiko: Kenya’s Moment to End Maternal and Child Deaths
Introduction: A Turning Point for Kenya’s Maternal and Child Health Kenya stands at a critical juncture in the fight against maternal and child mortality. A new report, amplified by voices from influential health leaders, argues that this is the best time to accelerate progress—even amid tight budgets. At the center of this momentum is Samburu…
-
Replicate Bioscience Awarded Grants to Develop New srRNA Vaccines for HIV and Malaria
Overview: A Major Step Forward in Global Health The Gates Foundation has announced a significant investment in bioscience aimed at accelerating the development of new vaccines using the next-generation srRNA (self-replicating RNA) platform. The funding, totaling approximately $7 million, will support researchers as they advance antigen designs for malaria and HIV vaccines. This initiative seeks…
-
Bioscience Secures Gates Foundation Grant to Advance srRNA Vaccines for HIV and Malaria
Overview Bioscience has been awarded approximately $7 million in funding from the Gates Foundation to advance its novel srRNA vaccine platform for HIV and malaria. The grant supports the development of candidate vaccines aimed at addressing two of the world’s most persistent public health burdens. The funding is contingent on humanitarian licensing terms, underscoring a…
-
Bioscience Wins Grant for srRNA HIV and Malaria Vaccines
Overview: A Landmark Funding for srRNA Vaccine Innovation Bioscience has announced that it will receive a substantial grant from the Gates Foundation to support the development of new self-amplifying RNA (srRNA) vaccines aimed at HIV and malaria. The approximately $7 million award will fund early-stage research and preclinical activities, with the goal of delivering vaccine…
-
Lenacapavir PrEP Price Drop: From $28,000 to $40 Expands Access
What is Lenacapavir and how does it work as PrEP? Lenacapavir is a long-acting HIV prevention drug (PrEP) that is administered as an injection twice a year. In the European Union, it has been approved for preventive use under the brand name Yeytuo, with Gilead as the manufacturer. Early studies have shown near-total protection against…
-
Lenacapavir: HIV prevention price slashed for LMICs
What is Lenacapavir and why does it matter for HIV prevention? Lenacapavir, marketed under the brand name Yeytuo, is a long-acting HIV prevention treatment that is injected twice a year. The EU approval placed it among the few options designed to simplify and strengthen pre- exposure prophylaxis (PrEP) by reducing the burden of daily pills.…
-
HIV Prevention Breakthrough: Lenacapavir PrEP Price Drop Expands Global Access
Lenacapavir: A Breakthrough in HIV Prevention Lenacapavir, marketed as Yeytuo, has advanced HIV prevention by offering a long-acting injectable PrEP treatment. Unlike daily pills, it is given as an injection twice a year, a feature that could simplify adherence for many people at risk. In the European Union, lenacapavir has been approved as a preventive…